摘要
2型糖尿病是心血管疾病的危险因素,为进一步提高急性心肌梗死合并2型糖尿病患者的预后,目前提出的SLGT2抑制剂(Sodium-glucose co-transporter-2 inhibitors)的治疗效果得到认可,达格列净作为SLGT2抑制剂的代表药物,它的疗效及作用机制逐渐受到关注,本篇综述旨在对达格列净的治疗机制以及改善患者预后的多方面原理做出介绍,以期进一步提高对该药物的认知,提高急性心肌梗死合并2型糖尿病患者的治疗预后。
Type 2 diabetes mellitus is a risk factor for cardiovascular disease. In order to further improve the prognosis of patients with acute myocardial infarction and type 2 diabetes mellitus, SLGT2 inhibi-tors have been proposed. The therapeutic effect of (Sodium glucose co-transporter-2 inhibitors) is gradually recognized. As a representative drug of SLGT2 inhibitors, dapagliflozin’s efficacy and mechanism of action have gradually attracted attention. This review aims to introduce the thera-peutic mechanism of dapagliflozin and the various principles of improving patient prognosis, so as to further improve the cognition of this drug to improve the prognosis of patients with acute myo-cardial infarction complicated with type 2 diabetes mellitus.
出处
《临床医学进展》
2023年第2期1667-1672,共6页
Advances in Clinical Medicine
